S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD)
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000844092.71570.04 |
| _version_ | 1797287924630290432 |
|---|---|
| author | M. D’Agostino S. Bringhen R. Ria F. Ciceri A. P. Falcone M. Michieli M. Grasso F. Pane M. Quaresima F. Cattel M. Mirabile F. Fioritoni M. T. Petrucci V. Cotugno A. Capra S. Pezzatti M. L. Mosca Siez M. Cantonetti G. Margiotta Casaluci P. Bertazzoni R. Floris M. Offidani G. Pietrantuono A. Evangelista M. Boccadoro A. Larocca |
| author_facet | M. D’Agostino S. Bringhen R. Ria F. Ciceri A. P. Falcone M. Michieli M. Grasso F. Pane M. Quaresima F. Cattel M. Mirabile F. Fioritoni M. T. Petrucci V. Cotugno A. Capra S. Pezzatti M. L. Mosca Siez M. Cantonetti G. Margiotta Casaluci P. Bertazzoni R. Floris M. Offidani G. Pietrantuono A. Evangelista M. Boccadoro A. Larocca |
| author_sort | M. D’Agostino |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:41:52Z |
| format | Article |
| id | doaj.art-b7ca49ada07a40c4b360e62b7b9474b8 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:41:52Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-b7ca49ada07a40c4b360e62b7b9474b82024-03-02T03:51:53ZengWileyHemaSphere2572-92412022-06-01620120210.1097/01.HS9.0000844092.71570.04202206003-00201S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD)M. D’Agostino0S. Bringhen1R. Ria2F. Ciceri3A. P. Falcone4M. Michieli5M. Grasso6F. Pane7M. Quaresima8F. Cattel9M. Mirabile10F. Fioritoni11M. T. Petrucci12V. Cotugno13A. Capra14S. Pezzatti15M. L. Mosca Siez16M. Cantonetti17G. Margiotta Casaluci18P. Bertazzoni19R. Floris20M. Offidani21G. Pietrantuono22A. Evangelista23M. Boccadoro24A. Larocca251 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italy2 S.C. Farmacia Ospedaliera, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy1 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italy2 S.C. Farmacia Ospedaliera, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy1 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italy3 Unit of Clinical Epidemiology, A.O.U. Città della Salute e della Scienza di Torino and CPO Piemonte, Torino, Italy1 European Myeloma Network, (EMN), Italy1 European Myeloma Network, (EMN), Italyhttp://journals.lww.com/10.1097/01.HS9.0000844092.71570.04 |
| spellingShingle | M. D’Agostino S. Bringhen R. Ria F. Ciceri A. P. Falcone M. Michieli M. Grasso F. Pane M. Quaresima F. Cattel M. Mirabile F. Fioritoni M. T. Petrucci V. Cotugno A. Capra S. Pezzatti M. L. Mosca Siez M. Cantonetti G. Margiotta Casaluci P. Bertazzoni R. Floris M. Offidani G. Pietrantuono A. Evangelista M. Boccadoro A. Larocca S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) HemaSphere |
| title | S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) |
| title_full | S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) |
| title_fullStr | S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) |
| title_full_unstemmed | S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) |
| title_short | S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) |
| title_sort | s300 health related quality of life in transplant ineligible real life multiple myeloma patients treated with bortezomib melphalan prednisone vmp vs lenalidomide dexamethasone rd |
| url | http://journals.lww.com/10.1097/01.HS9.0000844092.71570.04 |
| work_keys_str_mv | AT mdagostino s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT sbringhen s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT rria s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT fciceri s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT apfalcone s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT mmichieli s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT mgrasso s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT fpane s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT mquaresima s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT fcattel s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT mmirabile s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT ffioritoni s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT mtpetrucci s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT vcotugno s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT acapra s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT spezzatti s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT mlmoscasiez s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT mcantonetti s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT gmargiottacasaluci s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT pbertazzoni s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT rfloris s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT moffidani s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT gpietrantuono s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT aevangelista s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT mboccadoro s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd AT alarocca s300healthrelatedqualityoflifeintransplantineligiblereallifemultiplemyelomapatientstreatedwithbortezomibmelphalanprednisonevmpvslenalidomidedexamethasonerd |